Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Obesity drives a global rise in metabolic-associated steatotic liver disease (MASLD), creating a significant health burden.
• Current MASLD treatments include lifestyle changes, weight loss, and medications like glucagon-like peptide-1 receptor agonists (GLP-1RAs).
• Resmetirom, a thyroid hormone receptor-β agonist, is a recent FDA-approved option for MASLD.

Purpose of the Study:

• To discuss the rationale for investigating the combination therapy of resmetirom and GLP-1RAs for MASLD management.
• To explore potential synergistic effects of combining these two distinct therapeutic agents.

Main Methods:

• Review of existing literature on resmetirom and GLP-1RAs in MASLD treatment.
• Discussion of the pharmacological mechanisms of action for both drug classes.
• Exploration of potential additive or synergistic benefits based on preclinical and clinical data.

Main Results:

• Both GLP-1RAs and resmetirom have shown efficacy in improving MASLD and related metabolic parameters individually.
• The combined use of resmetirom and GLP-1RAs has not been previously studied.
• A theoretical basis exists for synergistic effects due to complementary mechanisms.

Conclusions:

• Combining resmetirom and GLP-1RAs presents a promising, yet unexplored, therapeutic strategy for MASLD.
• Further research, including clinical trials, is warranted to evaluate the safety and efficacy of this combination therapy.
• This approach could potentially offer enhanced benefits for patients with MASLD and associated metabolic disorders.